ErbB antagonists patenting: "Playing chess with cancer"

Recent Patents on Biotechnology

Volumn 2, Issue 3, 2008, Pages 181-187

  Aifa, Sami ^a   Rebai, Ahmed ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

Author keywords

EGFR; ErbB; MAb; Resistance mutations; Therapy; TKI

Indexed keywords

AMINO ACIDS; CELL SIGNALING; CYTOLOGY; DISEASES; FACINGS; ONCOLOGY;

BREAST CANCER; CELL SURVIVAL; CELL-CYCLE PROGRESSION; EGFR; ERBB; MAB; RESISTANCE MUTATION; SOLID CANCER; THERAPY; TKI;

MONOCLONAL ANTIBODIES;

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE DERIVATIVE; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BINDING AFFINITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; PATENT; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 58149117726     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220808786240980     Document Type: Review

References (58)

1. Cohen S, Fava RA, Sawyer ST. Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. Proc Natl Acad Sci USA 1982; 79: 6237-6241.
2. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-527.
3. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-2058.
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signalling network: Receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
5. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-86.
6. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007; 13: 527-534.
7. Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003; 8: e1-13.
8. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787.
9. Kawamoto T, Sato J D, Le A, Polikoff J, Sato GH, Mendelshon J. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natt Acad Sci USA 1983; 80: 1337-1341.
10. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
11. Garrett T, McKern N, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763-773.
12. Aifa S, Aydin J, Nordvall G, Lundstrom I, Svensson SP, Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. Exp Cell Res 2005; 302: 108-114.
13. Aifa S, Miled N, Frikha F, Aniba MR, Svensson SP, Rebai A. Electrostatic interactions of peptides flanking the tyrosine kinase domain in the epidermal growth factor receptor provides a model for intracellular dimerization and autophosphorylation. Proteins 2006; 62: 1036-1043.
14. Zhang XGJ, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125: 1137-1149.
15. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425.
16. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neuoncogene. Science 1985; 230:1132-1139.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
18. Hudziak, R.M., Shepard, H.M., Ullrich, A., Fendly, B.M.: US5677171 (1997) and US5720954 (1998).
19. Hudziak, R.M., Ullrich, A., Fendly, B.M.: US5725856 (1998).
20. Lonberg, N., Kay, R.M.: US20045569825 (2004).
21. Kucherlapati, R., Jakobovits, A., Brenner, D.G., Capon, D.J., Klapholz, S.: US20046713610 (2004).
22. Carter, P.J., Presta, L.G.: US5821337 (1998).
23. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumour cells to tumour necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
24. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
25. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
26. Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab therapy: What's neu with herceptin resistance? Cancer Cell 2007; 12: 297-299.
27. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153-163.
28. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008; 13: 515-525.
29. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008. [Epub ahead of print]
30. Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol 2007; 8: 47-60.
31. Allison, D.E., Bruno, R., Lu, J.-F., Ng, C.M.: US20060165702A1 (2006).
32. Cai Z, Zhang G, Zhou Z, et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/ neu complexes. Oncogene 2008; 27: 3870-3874.
33. Schlessinger, J., Givol, D., Bellot, F., Kris R., Ricca, G.A., Cheadle, C., South, V.J.: US20016217866 (2001).
34. Jakobovits, A., Yang, X.D., Gallo, M., Jia, X.C.: US20016235883 (2001).
35. Mendelsohn, J., Kawamoto, T., Sato, G., Sato, J. D.: US 4943533 (1990).
36. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
37. Goldstein, N.I., Giorgio, N.A., Jones, S.T., Saldanha, J.W.: US20067060808 (2006).
38. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol 2001; 38:17-23.
39. Wu M, Rivkin A, Pham T. Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 2008; 30: 14-30.
40. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002; 2: 91-102.
41. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
42. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
43. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
44. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
45. Honegger AM, Dull TJ, Felder S, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987; 5: 199-209.
46. Wissner, A., Johnson, B.D., Floyd, M.B. Jr., Kitchen, D.B.: US5760041 (1998).
47. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor, J Biol Chem 2002; 277: 46265-46272.
48. Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs 2007; 67: 1125-1138.
49. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-2075.
50. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006; 103: 7795-7800.
51. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
52. Pao W, Wang T, Riley GJ, Miller VA, Pan Q, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinoma to Gefitinib or Erlotinib. PLOS Med 2005; 2: e17.
53. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
54. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68: 3314-3322.
55. Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 2007; 12: 99-110.
56. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6: 876-885.
57. Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs 2007; 67: 1125-1138.
58. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006; 5: 649-659.